TGA Provisionally Approves Pfizer COVID-19 Vaccine

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on telegram
Telegram

TGA Provisionally Approves Pfizer COVID-19 Vaccine.

By Australian Government | Dept. of Health

The Therapeutic Goods Administration (TGA) has granted provisional approval to Pfizer Australia Pty Ltd for its COVID-19 vaccine, COMIRNATY, making it the first COVID-19 vaccine to receive regulatory approval in Australia.

Following a thorough and independent review of Pfizer’s submission, the TGA has decided that this vaccine meets the high safety, efficacy and quality standards required for use in Australia.

COMIRNATY is provisionally approved and included in the Australian Register of Therapeutic Goods (ARTG) for active immunisation to prevent coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, in individuals 16 years of age and older.

Provisional approval of this vaccine is valid for two years and means it can now be legally supplied in Australia. The approval is subject to certain strict conditions, such as the requirement for Pfizer to continue providing information to the TGA on longer term efficacy and safety from ongoing clinical trials and post-market assessment. COMIRNATY has been shown to prevent COVID-19 however it is not yet known whether it prevents transmission or asymptomatic disease.

Australians can be confident that the TGA’s review process of this vaccine was rigorous and of the highest standard. The decision to provisionally approve the vaccine was also informed by expert advice from the Advisory Committee on Vaccines (ACV), an independent committee with expertise in scientific, medical and clinical fields including consumer representation.

The TGA will continue to actively monitor the safety of the Pfizer vaccine both in Australia and overseas and will not hesitate to take action if safety concerns are identified. As an extra check, the TGA laboratories will undertake batch assessment of each batch of the vaccine before it can be supplied in Australia.

The TGA has published a series of regulatory documents that relate to this decision, including the Australian Public Assessment Report (AusPAR) and the decision summary, which provide details about the evidence that the TGA reviewed to support the provisional approval of the vaccine. The Product Information, FAQs and information on labelling and batch testing are also available on the COVID-19 vaccines hub.

Further information on the COVID-19 vaccine rollout is available on the Department of Health website.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on telegram
Telegram

Never miss any important news. Subscribe to our newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

McIntyre Report

Top 10 Crypto

in USD

in AUD

in GBP

in CAD

Current Price of Bitcoin 2.0

ANR Meme Report

with Nadine Roberts

Episode 002

21st Century Political System

Play Video

Enter email to receive ANR News articles ,2 free ebooks, plus the Global Health Organisation Report

Editor's Pick

Enter email to receive ANR News articles, 2 free e-books, plus the Global Health Organisation Report

Donate Now to Help Take Back Our World

$1000 Donation Turns Into $4000 of the New Global Currency

OWC (Our World Coin) Sponsorship Offer

If you donate to the Resistance you will receive major incentives.

Such as the following in Our World Coin which lists early 2022.

Plus if you donate over $2500 you will also receive 20% in Bitcoin 2.0